Bildkälla: Stockfoto

Xbrane Biopharma Q1 2024: Softer than anticipated - Redeye

Redeye leaves its initial comments on Xbrane's Q1 report, which came in softer than we had pencilled on both revenues and EBIT. However, sales to end customer grew 30% q/q which is on track with expectations.

Redeye leaves its initial comments on Xbrane's Q1 report, which came in softer than we had pencilled on both revenues and EBIT. However, sales to end customer grew 30% q/q which is on track with expectations.
Börsvärldens nyhetsbrev
ANNONSER